$FOLD
AMICUS THERAPEUTICS, INC.

2021 Q2 Form 10-Q Financial Statement

#000117887921000008 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $77.41M $62.35M $60.53M
YoY Change 24.15% 41.29% 77.77%
Cost Of Revenue $8.380M $6.676M $6.552M
YoY Change 25.52% 24.39% 61.58%
Gross Profit $69.03M $55.68M $53.97M
YoY Change 23.99% 43.63% 79.96%
Gross Profit Margin 89.17% 89.29% 89.17%
Selling, General & Admin $42.28M $34.66M $40.22M
YoY Change 21.98% -18.6% -9.23%
% of Gross Profit 61.24% 62.25% 74.51%
Research & Development $63.00M $69.61M $89.12M
YoY Change -9.49% -1.93% 37.97%
% of Gross Profit 91.27% 125.03% 165.12%
Depreciation & Amortization $1.567M $2.039M $1.764M
YoY Change -23.15% 76.69% 78.0%
% of Gross Profit 2.27% 3.66% 3.27%
Operating Expenses $107.9M $107.0M $132.0M
YoY Change 0.79% -7.09% 18.66%
Operating Profit -$38.83M -$51.35M -$78.06M
YoY Change -24.37% -32.82% -3.96%
Interest Expense $8.150M $3.635M $3.729M
YoY Change 124.21% -21.41% -42.22%
% of Operating Profit
Other Income/Expense, Net $234.0K $5.326M -$8.316M
YoY Change -95.61% -707.3% -865.75%
Pretax Income -$46.70M -$48.79M -$88.59M
YoY Change -4.28% -41.8% -26.26%
Income Tax $4.525M $3.703M $361.0K
% Of Pretax Income
Net Earnings -$51.23M -$52.49M -$88.95M
YoY Change -2.41% -37.92% -26.06%
Net Earnings / Revenue -66.17% -84.19% -146.96%
Basic Earnings Per Share -$0.19 -$0.20
Diluted Earnings Per Share -$0.19 -$0.20 -$346.1K
COMMON SHARES
Basic Shares Outstanding 266.4M shares 258.0M shares 257.2M shares
Diluted Shares Outstanding 266.4M shares 258.0M shares

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $383.1M $309.6M $338.9M
YoY Change 23.73% -46.22% -22.68%
Cash & Equivalents $176.5M $164.6M $123.2M
Short-Term Investments $206.5M $145.0M $215.6M
Other Short-Term Assets $24.18M $18.30M $15.70M
YoY Change 32.11% -8.96% 15.44%
Inventory $24.09M $12.98M $12.83M
Prepaid Expenses
Receivables $49.17M $43.04M $40.56M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $480.5M $383.9M $407.9M
YoY Change 25.17% -39.53% -15.55%
LONG-TERM ASSETS
Property, Plant & Equipment $42.37M $46.95M $47.69M
YoY Change -9.76% 207.37% 258.93%
Goodwill $197.8M $197.8M $197.8M
YoY Change 0.0% 0.0% 0.0%
Intangibles $23.00M $23.00M $23.00M
YoY Change 0.0% 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $21.20M $25.88M $29.41M
YoY Change -18.07% 115.01% 161.11%
Total Long-Term Assets $306.4M $317.6M $330.4M
YoY Change -3.52% 12.15% 17.31%
TOTAL ASSETS
Total Short-Term Assets $480.5M $383.9M $407.9M
Total Long-Term Assets $306.4M $317.6M $330.4M
Total Assets $786.9M $701.5M $738.3M
YoY Change 12.18% -23.59% -3.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.76M $14.31M $16.24M
YoY Change -3.8% -82.99% -73.2%
Accrued Expenses $78.43M $94.00M $74.20M
YoY Change -16.56% 3381.48% 2868.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $112.0M $108.3M $91.71M
YoY Change 3.41% 20.94% 39.24%
LONG-TERM LIABILITIES
Long-Term Debt $390.4M $150.0M $149.7M
YoY Change 160.29% 0.6% -11.32%
Other Long-Term Liabilities $6.535M $4.511M $4.214M
YoY Change 44.87% 13.14% 16.76%
Total Long-Term Liabilities $6.535M $4.511M $4.214M
YoY Change 44.87% 13.14% 16.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $112.0M $108.3M $91.71M
Total Long-Term Liabilities $6.535M $4.511M $4.214M
Total Liabilities $573.0M $340.5M $335.8M
YoY Change 68.28% 7.08% 7.26%
SHAREHOLDERS EQUITY
Retained Earnings -$2.200B -$1.900B -$1.900B
YoY Change 15.79% 18.75% 23.98%
Common Stock $2.367B $2.253B $2.241B
YoY Change 5.05% 2.24% 13.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $213.9M $361.0M $402.6M
YoY Change
Total Liabilities & Shareholders Equity $786.9M $701.5M $738.3M
YoY Change 12.18% -23.59% -3.45%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$51.23M -$52.49M -$88.95M
YoY Change -2.41% -37.92% -26.06%
Depreciation, Depletion And Amortization $1.567M $2.039M $1.764M
YoY Change -23.15% 76.69% 78.0%
Cash From Operating Activities -$35.93M -$33.52M -$107.9M
YoY Change 7.18% -42.68% 37.43%
INVESTING ACTIVITIES
Capital Expenditures -$364.0K -$1.070M $806.0K
YoY Change -65.98% -50.69% -72.62%
Acquisitions
YoY Change
Other Investing Activities $26.08M $71.08M $94.05M
YoY Change -63.31% -651.01% 13.3%
Cash From Investing Activities $25.71M $70.01M $93.25M
YoY Change -63.28% -564.57% 16.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.234M 4.090M -$1.487M
YoY Change -45.38% -97.92% -108.55%
NET CHANGE
Cash From Operating Activities -35.93M -33.52M -$107.9M
Cash From Investing Activities 25.71M 70.01M $93.25M
Cash From Financing Activities 2.234M 4.090M -$1.487M
Net Change In Cash -7.985M 40.58M -$20.45M
YoY Change -119.68% -66.97% -223.53%
FREE CASH FLOW
Cash From Operating Activities -$35.93M -$33.52M -$107.9M
Capital Expenditures -$364.0K -$1.070M $806.0K
Free Cash Flow -$35.56M -$32.45M -$108.7M
YoY Change 9.59% -42.37% 33.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001178879
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33497
dei Entity Registrant Name
EntityRegistrantName
Amicus Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
71-0869350
dei Entity Address Address Line1
EntityAddressAddressLine1
3675 Market Street,
dei Entity Address City Or Town
EntityAddressCityOrTown
Philadelphia,
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19104
dei City Area Code
CityAreaCode
(215)
dei Local Phone Number
LocalPhoneNumber
921-7600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
FOLD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
266555274 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176538000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163240000 USD
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
206530000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
320029000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49172000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
46923000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
24086000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
19556000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24176000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29721000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
480502000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
579469000 USD
CY2021Q2 fold Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases
AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
8150000 USD
CY2020Q4 fold Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases
AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
7574000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22028000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23296000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17410000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14487000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42365000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43863000 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23000000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23000000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
197797000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
197797000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21200000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19095000 USD
CY2021Q2 us-gaap Assets
Assets
786892000 USD
CY2020Q4 us-gaap Assets
Assets
886520000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13762000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17063000 USD
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
71325000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
96841000 USD
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
19800000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8900000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7106000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6872000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
111993000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
129676000 USD
CY2021Q2 us-gaap Deferred Credits And Other Liabilities Noncurrent
DeferredCreditsAndOtherLiabilitiesNoncurrent
7406000 USD
CY2020Q4 us-gaap Deferred Credits And Other Liabilities Noncurrent
DeferredCreditsAndOtherLiabilitiesNoncurrent
7406000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
390434000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
389254000 USD
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7517000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
16925000 USD
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4896000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4896000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44201000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45604000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6535000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6379000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
572982000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
600140000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
266532536 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
266532536 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
262063461 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
262063461 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
2685000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2650000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2364494000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2308578000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
9255000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
8412000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-173000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-185000 USD
CY2021Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 USD
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
12387000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2162351000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2045462000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
213910000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286380000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
786892000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
886520000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77413000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62353000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
143815000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122878000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8380000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6676000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14919000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13228000 USD
CY2021Q2 us-gaap Gross Profit
GrossProfit
69033000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
55677000 USD
us-gaap Gross Profit
GrossProfit
128896000 USD
us-gaap Gross Profit
GrossProfit
109650000 USD
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
63003000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69611000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
127120000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
158731000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42276000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34657000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89002000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74872000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1021000 USD
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-715000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1492000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1646000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1567000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2039000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3171000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3803000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
107867000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
107022000 USD
us-gaap Operating Expenses
OperatingExpenses
220785000 USD
us-gaap Operating Expenses
OperatingExpenses
239052000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38834000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-51345000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-91889000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-129402000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
50000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
865000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
215000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
2380000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
8150000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
3635000 USD
us-gaap Interest Expense
InterestExpense
16142000 USD
us-gaap Interest Expense
InterestExpense
7364000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
234000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5326000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2966000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2990000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46700000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48789000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-110782000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-137376000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4525000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3703000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6107000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4064000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-51225000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52492000 USD
us-gaap Net Income Loss
NetIncomeLoss
-116889000 USD
us-gaap Net Income Loss
NetIncomeLoss
-141440000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
266398516 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
266398516 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257973329 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257973329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
265384865 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
265384865 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257548623 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257548623 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-51225000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52492000 USD
us-gaap Net Income Loss
NetIncomeLoss
-116889000 USD
us-gaap Net Income Loss
NetIncomeLoss
-141440000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
52000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-2090000 USD
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
184000 USD
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-554000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
235000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2116000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
843000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2080000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
3000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
122000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
3000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
66000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
457000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
248000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
247000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1659000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
855000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2328000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50978000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54151000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116034000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-139112000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
250896000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2500000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
244000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11736000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
235000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-51225000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
213910000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286380000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6661000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
14438000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32090000 USD
fold Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19230000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
21000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
843000 USD
us-gaap Net Income Loss
NetIncomeLoss
-116889000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
213910000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
402594000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4656000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
554000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8408000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
457000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2116000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52492000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
360953000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
476425000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10733000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
8097000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21004000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
248000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2080000 USD
us-gaap Net Income Loss
NetIncomeLoss
-141440000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
360953000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
32090000 USD
us-gaap Profit Loss
ProfitLoss
-116889000 USD
us-gaap Profit Loss
ProfitLoss
-141440000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1200000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
532000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3171000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3803000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
21004000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1492000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1646000 USD
fold Foreign Currency Remeasurement Gain Loss Before Tax
ForeignCurrencyRemeasurementGainLossBeforeTax
-3235000 USD
fold Foreign Currency Remeasurement Gain Loss Before Tax
ForeignCurrencyRemeasurementGainLossBeforeTax
-5604000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3127000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10388000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4445000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1351000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5265000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1375000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28485000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-23916000 USD
fold Increase Decrease In Noncurrent Operating Liabilities
IncreaseDecreaseInNoncurrentOperatingLiabilities
-1784000 USD
fold Increase Decrease In Noncurrent Operating Liabilities
IncreaseDecreaseInNoncurrentOperatingLiabilities
-1031000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108277000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-141460000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
258767000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
210139000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
145255000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
45005000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1234000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1876000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
112278000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
163258000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
389000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
38000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14438000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8097000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2599000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6661000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10734000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
19230000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11064000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1439000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3476000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13626000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20921000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166162000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146341000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179788000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167262000 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
67000 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
455000 USD
us-gaap Interest Paid Net
InterestPaidNet
15109000 USD
us-gaap Interest Paid Net
InterestPaidNet
10709000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
191000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
502000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4526000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1956000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2200000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of June 30, 2021 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. The Company's accounts receivable at June 30, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77413000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62353000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
143815000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122878000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176500000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176538000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
176538000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
383043000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
383068000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176538000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
176538000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
206505000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
206530000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
383043000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 USD
CY2021Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
383068000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163240000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
163240000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
483256000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
483269000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163240000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
163240000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
320016000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
320029000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
483256000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
CY2020Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
483269000 USD
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 USD
CY2020 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
17200000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
124900000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176538000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164573000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3250000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2689000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179788000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167262000 USD
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7619000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5547000 USD
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11306000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7693000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5161000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6316000 USD
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
24086000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
19556000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
390434000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
389254000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
4100 shares
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7604000 USD
CY2020Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3410000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15125000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6995000 USD
CY2021Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
383000 USD
CY2020Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
268000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
720000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
474000 USD
CY2021Q2 fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
262000 USD
CY2020Q2 fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
33000 USD
fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
485000 USD
fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
58000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14032000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2453000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
945000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
524000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
54000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.21
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14962000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15100000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13586000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15000000.0 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9074000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
14800000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11736000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8408000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32090000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21004000 USD
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
210711000 USD
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
27317000 USD
CY2021Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4233000 USD
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
31550000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
324055000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
25825000 USD
CY2020Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4078000 USD
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
29903000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
26296000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
23612000 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
25825000 USD
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
22681000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1021000 USD
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-715000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1492000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1646000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27317000 USD
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
24327000 USD
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27317000 USD
CY2020Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
24327000 USD
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
19800000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-51225000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52492000 USD
us-gaap Net Income Loss
NetIncomeLoss
-116889000 USD
us-gaap Net Income Loss
NetIncomeLoss
-141440000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
266398516 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
266398516 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257973329 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257973329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
265384865 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
265384865 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257548623 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257548623 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28915000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22832000 shares

Files In Submission

Name View Source Status
0001178879-21-000008-index-headers.html Edgar Link pending
0001178879-21-000008-index.html Edgar Link pending
0001178879-21-000008.txt Edgar Link pending
0001178879-21-000008-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fold-06302021xex311.htm Edgar Link pending
fold-06302021xex312.htm Edgar Link pending
fold-06302021xex321.htm Edgar Link pending
fold-20210630.htm Edgar Link pending
fold-20210630.xsd Edgar Link pending
fold-20210630_cal.xml Edgar Link unprocessable
fold-20210630_def.xml Edgar Link unprocessable
fold-20210630_htm.xml Edgar Link completed
fold-20210630_lab.xml Edgar Link unprocessable
fold-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending